Loomis, Sayles & Company
EPZM

Loomis, Sayles & Company’s Epizyme, Inc EPZM Stock Holding History

Loomis, Sayles & Company’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,386,996
Closed -$22.3M – 745
2020
Q2 		$22.3M Buy
1,386,996
+120,452
+10% +$2.1M 0.04% 205
2020
Q1 		$19.6M Sell
1,266,544
-334,749
-21% -$7.19M 0.04% 165
2019
Q4 		$39.4M Sell
1,601,293
-5,207
-0.3% -$77.3K 0.07% 115
2019
Q3 		$16.6M Buy
+1,606,500
New +$20.3M 0.03% 243

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Loomis, Sayles & Company's EPZM Position: Q3 2020 in Review

Loomis, Sayles & Company sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 1,386,996 shares — an estimated $22.3M sold.

Loomis, Sayles & Company first reported a position in EPZM in Q3 2019 and held it in 4 quarters. The position peaked at $39.4M in Q4 2019. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Loomis, Sayles & Company reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,386,996 Epizyme, Inc shares in Q3 2020, an estimated $22.3M.
  • Loomis, Sayles & Company first reported a position in Epizyme, Inc in Q3 2019 and held it in 4 quarters.
  • Loomis, Sayles & Company's Epizyme, Inc position peaked at $39.4M in Q4 2019.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Loomis, Sayles & Company's 13F filing for Q3 2020, filed 12 Nov 2020.